Evidence map›Paper›PMID 41683782›Full record

ArticleInternational journal of molecular sciences2026

Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Marwa Tantawy, Danxin Wang, Mohammed Gbadamosi, Fahong Yu, Yanping Zhang, Mohammed E Alomar, Kenneth H Shain, Rachid C Baz, Katelyn A Bruno, Yan Gong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marwa TantawyDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0001-6767-1093
Danxin WangDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0002-7134-3065
Mohammed GbadamosiDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
Fahong YuBioinformatics at Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0002-6670-8795
Yanping ZhangGene Expression & Genotyping at Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32610, USA.
Mohammed E AlomarCardio-Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33216, USA.
Kenneth H ShainDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33216, USA.
Rachid C BazDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33216, USA.ORCID 0000-0003-4538-4733
Katelyn A BrunoCardio-Oncology Working Group, University of Florida Health Cancer Institute, Gainesville, FL 32610, USA.ORCID 0000-0001-8980-6059
Yan GongDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0002-8218-1620

Funding

University of Florida College of Pharmacy NA
6 · The paper itself

Abstract

The mechanisms underlying carfilzomib (CFZ)-induced cardiotoxicity remain incompletely elucidated. In this study, we used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to characterize the transcriptional impact of CFZ and to evaluate whether atorvastatin could prevent these deleterious transcriptional changes. hiPSC-CMs were treated with 1 µM CFZ, CFZ + atorvastatin, atorvastatin, or vehicle control, followed by RNA sequencing, differential expression analyses, and pathway analyses. Transcriptomic profiling revealed a marked upregulation of genes in multiple proteasome subunits, including ATPase components (

Indexed as

AtorvastatinGene Expression RegulationInduced Pluripotent Stem CellsMyocytes, CardiacOligopeptidesTranscription, GeneticCardiotoxicityGene Expression ProfilingHumansTranscriptomeAtorvastatincarfilzomibOligopeptidesatorvastatincardiotoxicitycarfilzomibinduced pluripotent stem cells

Identifiers

PMID41683782
PMCPMC12898222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.